Rezatapopt

Nutshell Therapeutics received FDA clearance for NTS071, a novel p53 Y220C allosteric reactivator, to begin Phase 1 clinical trials in the US, advancing a potential tumor-agnostic therapy for multiple cancer types.

Researchers from Sylvester Comprehensive Cancer Center will deliver 9 oral presentations, 4 rapid oral presentations, and 51 poster presentations at the upcoming ASCO 2025 Annual Meeting, showcasing significant advances across multiple cancer types.

Perspective Therapeutics' VMT-α-NET program shows promising early results in neuroendocrine tumors, with no dose-limiting toxicities observed in Phase 1/2a trials.

PMV Pharmaceuticals' PYNNACLE trial advances with Rezatapopt monotherapy for TP53 Y220C mutated solid tumors, showing over 75% site activation across multiple regions.

PMV Pharmaceuticals is advancing PC14586 (rezatapopt) in a Phase 2 monotherapy trial (PYNNACLE) for solid tumors with p53 Y220C mutations, with interim data expected by mid-2025.